Accessibility Menu
AlphaTON Capital logo

AlphaTON Capital(NASDAQ) PRTG

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-100%
5 Year-100%
1 Year-98%
1 Month-11%
N/A
AlphaTON Capital last closing stock price
MetricPriceDate
Last closeUSD 0.172026-09-01
AlphaTON Capital stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.05%USD 0.172026-08-25
1 month-11.11%USD 0.202026-07-31
3 month-37.97%USD 0.282026-06-03
Year to date-70.92%USD 0.602025-12-31
1 year-97.58%USD 7.202025-08-29
3 year-99.63%USD 47.002023-09-01
5 year-99.96%USD 438.002021-09-02
Since inception-99.97%USD 670.002013-06-05

AlphaTON Capital Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$6.77M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 19, 2025

PRTG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AlphaTON Capital

Portage Biotech Inc. is a biotechnology company focused on the discovery and advancement of innovative pharmaceutical and biotechnological products. The company operates through various subsidiaries and has a robust pipeline of therapeutic candidates aimed at addressing significant medical needs.

Products and Services
  • IMM60, an activator for iNKT cells
  • INT230-6, currently in Phase I/II trials for solid tumors
  • CellPorter, a platform utilizing cell-permeable peptides
Growth Outlook
  • Strong pipeline with multiple candidates in various stages of development
  • Focus on immuno-oncology and novel therapeutic approaches
  • Potential for partnerships to enhance research and development capabilities
Financial Highlights
  • Recent quarterly net income of -$1,875,500, reflecting ongoing R&D investments
  • Cash and cash equivalents of $1,670,000 as of March 31, 2025
  • Operating expenses of $1,470,000 in the latest quarter, indicating sustained operational focus
Portage Biotech Inc. is dedicated to advancing its innovative therapies, particularly in the fields of immuno-oncology and targeted treatments. The company’s diverse product pipeline includes several promising candidates, such as IMM60 and INT230-6, which are designed to address critical health challenges. The ongoing clinical trials and research initiatives highlight the company's commitment to developing effective therapies. Financially, Portage Biotech is currently in a phase of significant investment in research and development, which is reflected in its recent net income figures. The company maintains a solid cash position, allowing it to continue its operational and developmental activities. The focus on innovative solutions in the biotechnology sector positions Portage Biotech as a noteworthy entity for potential investors interested in the healthcare industry.
AI Generated • Aug 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Brittany Kaiser

Website

www.portagebiotech.com

Headquarters

Tortola, VG1110, VG

PRTG Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-25275.26%

Net Income Margin

-44767.01%

Return on Equity

-748.11%

Return on Capital

-313.51%

Return on Assets

-222.35%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$8.00K

Operating Income

-$7.38M

EBITDA

-$7.38M

Operating Cash Flow

-$5.46M

Capital Expenditure

$0.00

Free Cash Flow

-$5.46M

Cash & ST Invst.

$1.67M

Total Debt

$0.00

AlphaTON Capital Performance Analysis

AlphaTON Capital annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 0N/A
20242024-03-31USD 0N/A
20252025-03-31USD 0N/A
20262026-03-31USD 97,000N/A
AlphaTON Capital sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-06-30N/A
Q22024-09-30N/A
Q32024-12-31N/A
Q42025-03-31N/A
AlphaTON Capital annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -129.80402.4%
20242024-03-31USD -77.90-40.0%
20252025-03-31USD -5.72-92.7%
20262026-03-31USD -4.18-27.0%
AlphaTON Capital sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-06-30-25.4%
Q22024-09-3020.3%
Q32024-12-31-14.3%
Q42025-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

7

N/A

Net Income

-$1.88M

+92.5%

EBITDA

-$1.47M

+94.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$1.67M

-66.8%

Total Debt

$0.00

-100.0%

Accounts Receivable

$12.00K

-69.2%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-2.22%

N/A

Return on Invested Capital

-3.61%

N/A

Free Cash Flow

-$1.11M

+65.5%

Operating Cash Flow

-$1.11M

+65.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMNNImunon, Inc.
$1.60-1.84%
PIRSPieris Pharmaceuticals, Inc.
$13.60-15.58%
CYADCelyad Oncology S.A.
$0.47-12.96%
WENAAnew Medical, Inc.
$0.73-3.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$14.06+0.06%
NVDANvidia
$217.44-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.33-0.06%
INTCIntel
$88.97-0.01%

Questions About PRTG

What is the current price of AlphaTON Capital?

AlphaTON Capital is trading at N/A per share.

What is the 52-week range for AlphaTON Capital?

Over the past 52 weeks, AlphaTON Capital has traded between N/A and N/A.

How much debt does AlphaTON Capital have?

As of the most recent reporting period, AlphaTON Capital reported total debt of $0.00.

How much cash does AlphaTON Capital have on hand?

AlphaTON Capital reported $183.00K in cash and cash equivalents in its most recent financial results.

What is AlphaTON Capital’s dividend yield?

AlphaTON Capital does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services